Literature DB >> 11397645

Vascular effects of estrogens: arterial protection versus venous thrombotic risk.

M P Bracamonte1, V M Miller.   

Abstract

Mechanisms by which estrogen reduces the risk of arterial disease, while simultaneously increasing the risk of venous thrombosis in postmenopausal women, are not clearly understood. In addition to providing beneficial arterial effects on the lipid profile, estrogen both increases production of nitric oxide and decreases production of endothelin-1 from arterial endothelium, decreases intracellular calcium in arterial smooth muscle and might favor fibrinolysis. All of these effects could act in concert to protect against development of arterial occlusive disease. However, comparable effects on venous endothelium and smooth muscle have not been studied systematically, and although blood elements such as platelets and leukocytes contain estrogen receptors, much remains to be learned about the effect that dose and duration of estrogen-treatment might have upon these cells. An integrative approach to understanding the actions of estrogen on the venous system and the interaction of blood elements with the vascular wall is necessary before new therapeutic interventions will provide arterial protection with no risk of venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397645     DOI: 10.1016/s1043-2760(01)00406-4

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  13 in total

Review 1.  Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes.

Authors:  James H Segars; Paul H Driggers
Journal:  Trends Endocrinol Metab       Date:  2002-10       Impact factor: 12.015

2.  Placental development during early pregnancy in sheep: nuclear estrogen and progesterone receptor mRNA expression in the utero-placental compartments.

Authors:  Anna T Grazul-Bilska; Soumi Bairagi; Aree Kraisoon; Sheri T Dorsam; Arshi Reyaz; Chainarong Navanukraw; Pawel P Borowicz; Lawrence P Reynolds
Journal:  Domest Anim Endocrinol       Date:  2018-09-26       Impact factor: 2.290

Review 3.  Vascular actions of estrogens: functional implications.

Authors:  Virginia M Miller; Sue P Duckles
Journal:  Pharmacol Rev       Date:  2008-06-25       Impact factor: 25.468

4.  Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.

Authors:  Greta L Hoetzer; Brian L Stauffer; Heather M Irmiger; Marilyn Ng; Derek T Smith; Christopher A DeSouza
Journal:  J Physiol       Date:  2003-06-18       Impact factor: 5.182

Review 5.  Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.

Authors:  Syed Imran Ali Shah
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun

6.  Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.

Authors:  Iain Phillips; Syed I A Shah; Trinh Duong; Paul Abel; Ruth E Langley
Journal:  Oncol Hematol Rev       Date:  2014

7.  17ß-estradiol antagonizes the down-regulation of ERα/NOS-3 signaling in vascular endothelial dysfunction of female diabetic rats.

Authors:  Yi Han; Xiaozhen Li; Suming Zhou; Guoliang Meng; Yujiao Xiao; Wen Zhang; Zhuoying Wang; Liping Xie; Zhen Liu; Hui Lu; Yong Ji
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

8.  Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause.

Authors:  Virginia M Miller; Vesna D Garovic; Kejal Kantarci; Jill N Barnes; Muthuvel Jayachandran; Michelle M Mielke; Michael J Joyner; Lynne T Shuster; Walter A Rocca
Journal:  Biol Sex Differ       Date:  2013-03-28       Impact factor: 5.027

9.  Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Authors:  Ruth E Langley; Fay H Cafferty; Abdulla A Alhasso; Stuart D Rosen; Subramanian Kanaga Sundaram; Suzanne C Freeman; Philip Pollock; Rachel C Jinks; Ian F Godsland; Roger Kockelbergh; Noel W Clarke; Howard G Kynaston; Mahesh Kb Parmar; Paul D Abel
Journal:  Lancet Oncol       Date:  2013-03-04       Impact factor: 41.316

10.  Dietary isoflavone intake, urinary isoflavone level, and their relationship with metabolic syndrome diagnostic components in korean postmenopausal women.

Authors:  Mi Hyun Kim; Yun Jung Bae
Journal:  Clin Nutr Res       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.